Monopar Therapeutics Risk Adjusted Performance
| MNPR Stock | | | USD 46.82 0.05 0.11% |
Monopar Therapeutics risk-adjusted-performance technical analysis lookup allows you to check this and other technical indicators for Monopar Therapeutics or any other equities. You can select from a set of available technical indicators by clicking on the link to the right. Please note, not all equities are covered by this module due to inconsistencies in global equity categorizations and data normalization technicques. Please check also
Equity Screeners to view more equity screening tools
Monopar Therapeutics has current Risk Adjusted Performance of 0.0517.
RAP | = | (ER[a] - RFR) * STD[b])/STD[b]RFR |
| = | 0.0517 | |
Monopar Therapeutics Risk Adjusted Performance Peers Comparison
Monopar Risk Adjusted Performance Relative To Other Indicators
Monopar Therapeutics is regarded
fifth in risk adjusted performance category among its peers. It is currently under evaluation in maximum drawdown category among its peers reporting about
535.48 of Maximum Drawdown per Risk Adjusted Performance. The ratio of Maximum Drawdown to Risk Adjusted Performance for Monopar Therapeutics is roughly
535.48
Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.